Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms.

Kidney international - 1 Mar 2010

Caplin Ben, Nitsch Dorothea, Gill Herpreet, Hoefield Richard, Blackwell Scott, MacKenzie Douglas, Cooper Jackie A, Middleton Rachel J, Talmud Philippa J, Veitch Peter, Norman Jill, Wheeler David C, Leiper James M

Abstract excerpt

In patients with chronic kidney disease, high plasma levels of the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, are thought to contribute to decline in renal function. Here we took a candidate gene approach to determine any causal role of asymmetric dimethylarginine in the progression of chronic kidney disease. The impact of single-nucleotide polymorphisms in the genes encoding the two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amidohydrolases
Share to Arginine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Cross-Sectional Studies

Share to Enzyme Inhibitors

Share to Glomerular Filtration Rate

Share to Kidney Failure, Chronic

Share to Longitudinal Studies

Source

Identifiers

PMID: 20010544
DOI: 10.1038/ki.2009.463

Genes

DDAH1
DDAH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms.PMID 20010544Read ↗

Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?Semantic proximity Read ↗

The role of DDAH and ADMA in kidney diseaseSemantic proximity Read ↗

A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with chronic kidney disease.Semantic proximity Read ↗

Genome-wide association study of L-arginine and dimethylarginines reveals novel metabolic pathway for symmetric dimethylarginine.Semantic proximity Read ↗

Apolipoprotein E polymorphism modulation of asymmetric dimethylarginine in hypertensive patients is determined by renal function.Semantic proximity Read ↗

Distribution of dimethylarginine-dimethylaminohydrolase-II (DDAH2) gene polymorphism in hemodialysis patients.Semantic proximity Read ↗

Relationship between dimethylarginine dimethylaminohydrolase gene variants and asymmetric dimethylarginine in patients with rheumatoid arthritis.Semantic proximity Read ↗

The impact of methylarginine metabolism on disease progression in idiopathic pulmonary fibrosisSemantic proximity Read ↗

ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis.Semantic proximity Read ↗

Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression.Semantic proximity Read ↗

Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine.Semantic proximity Read ↗

Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.